Edition:
India

People: Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,475.20INR
16 Nov 2018
Change (% chg)

Rs13.25 (+0.54%)
Prev Close
Rs2,461.95
Open
Rs2,465.10
Day's High
Rs2,495.00
Day's Low
Rs2,440.20
Volume
29,825
Avg. Vol
79,945
52-wk High
Rs2,687.45
52-wk Low
Rs1,888.00

Carter, Bruce 

Dr. Bruce L. A. Carter, Ph.D., serves as a Non-Executive Independent Director of Dr.Reddy's Laboratories Ltd. He joined our Board in 2008, prior to which he was the Chairman of the Board and Chief Executive Offi cer of ZymoGenetics Inc., USA. He has also served as the Corporate Executive Vice President and Chief Scientifi c Offi cer for Novo Nordisk A/S. Dr. Carter held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin, from 1975 to 1982. Dr. Carter is also on the Board of Xencor Inc., Enanta Pharmaceutical Inc. and TB Alliance, all in the US and our wholly-owned subsidiary, Aurigene Discovery Technologies Ltd., in India. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.

Basic Compensation

Total Annual Compensation, INR 8,766,000
Restricted Stock Award, INR --
Long-Term Incentive Plans, INR --
All Other, INR --
Fiscal Year Total, INR 8,766,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --